- $23.34bn
- $27.11bn
- $3.72bn
Press Digest: Wall Street Journal - September 29
Brief: Genmab To Buy Merus For USD 8.0 Billion
Genmab to buy Dutch cancer drugmaker Merus for $8 billion (updated)
Genmab nears deal to acquire Dutch cancer drugmaker Merus, Bloomberg News reports
Brief: Genmab Is Said To Near Deal To Buy Cancer Drugmaker Merus - Bloomberg News
European pharma stocks largely steady amid new US tariff onslaught
Europe Research Roundup: Ashtead Group, Diploma ,ISS
Brief: Genmab Announces Updated Results From Phase 2 Epcore Nhl-6 Study
Europe Research Roundup: Alfen, Dermapharm Holding, Fugro
Brief: Genmab Gets FDA Breakthrough Therapy Designation For Rinatabart Sesutecan
Europe Research Roundup: Airbus, BBVA, Domino's Pizza
Brief: Genmab Says Phase 3 EPCORE FL-1 Clinical Trial Met Dual Primary Endpoints In Patients With R/R FL
Brief: Genmab H1 Operating Profit Rises To $548 Mln
Brief: Genmab Says 2025 Revised FY Revenue Outlook 3,500 USD Million To 3,700 USD Million
Genmab rises after blood cancer drug meets main goal of late-stage study
Brief: Genmab Announces Phase 3 Epcore Clinical Trial Results
Brief: Genmab Says Net Sales Of Darzalex In Q2 $3,539 Mln
Europe Research Roundup: Aegon, AXA, Sonova Holding
Europe Research Roundup: Heidelberg Materials, Krones, Mondi